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Background: Genome-wide association studies have identified 
15q25 and 5p15 as lung cancer risk chromosomal regions in whites. 
The genetic structures of these loci differ between Asians and whites, 
however, indicating the need for additional studies in Asian popula-
tions. To examine the impact of 15p25 and 5p15 on lung cancer risk 
and smoking intensity, we conducted a case-control study in Japanese 
population. We also examined whether these loci modify the effect of 
smoking behavior on lung cancer risk.
Methods: Subjects were 716 Japanese patients with lung cancer 
and 716 controls. Associations were examined by logistic regression 
models with adjustment for potential confounders.
Results: We found that the variants of rs12914385 and rs931794 
on 15q25 modified the effect of cumulative tobacco smoking on 
lung cancer risk but that these two loci showed no statistically sig-
nificant main effects on lung cancer risk. Compared with never 
smoking without the risk allele of rs931794, odds ratio for heavy 
smoking without the risk allele was 4.03 (95% confidence interval: 
2.45–6.62) and that with the risk allele was 8.09 (5.09–12.9), and 
the joint effect of rs931734 and cumulative tobacco consumption 
was statistically significant (p
interaction 
 0.001). A similar impact was 
observed with rs12914385 at chromosome 15q25 (p
interaction 
5 0.021). 
Associations for the TERT-CLPM1L locus on 5p15 with lung cancer 
risk in Japanese patients were of a similar magnitude to those in 
whites.
Conclusions: These results support the contribution of 15q25 and 
5p15 to lung cancer and indicate that the 15q25 region modifies the 
well-established effect of smoking on the risk of lung cancer in a 
Japanese population.
Key Words: Lung cancer, Genetic susceptibility, 15q25, 5p15, 
Smoking.
(J Thorac Oncol. 2012;7: 790–798)
Lung cancers are substantially attributable to tobacco smok-ing. Multiple powerful carcinogens and nicotine in tobacco 
smoke induce malignancies, including lung cancer. Because 
not all smokers develop lung cancer, however, lung carcino-
genesis has long been thought to be influenced by genetic 
differences in susceptibility to tobacco carcinogens, namely 
gene-environment interaction.1
An international genetic association study by the 
International Lung Cancer Consortium2 recently confirmed 
the findings of earlier genome-wide association studies 
(GWAS)3–5 of lung cancer susceptibility loci at 15q25 and 
5p15 in white populations. Given the marked differences in the 
characteristics of lung cancer between East Asians and whites6 
and the differences in linkage disequilibrium (LD) structures 
in these regions,7 it is important to evaluate the contribution of 
these regions in East Asian populations in combination with 
environmental factors, including smoking.
In addition to its suggested role in lung cancer risk, the 
region on chromosome 15q25.1, which includes the CHRNA5-
CHRNA3-CHRNB3 cluster of cholinergic nicotinic receptor 
subunit genes, has been confirmed to be associated with a 
number of smoking-related traits, including nicotine depen-
dence, cigarettes smoked per day, and heavy smoking, in 
both GWAS3,8,9 and in candidate gene association studies.2,9–14 
Further, it has been reported to be the most significant asso-
ciation in recent genome-wide meta-analyses in whites.15–17 
Nevertheless, no consensus on the relative impact of chromo-
some 15q25 loci on smoking behavior versus a direct lung 
carcinogenic effect on the risk of lung cancer has yet been 
reached. The HapMap project7 revealed that the risk alleles 
of the single-nucleotide polymorphisms (SNPs) at chromo-
some 15q25, rs8034191 and rs16969968, identified in the pre-
vious GWAS among whites, have extremely low frequencies 
in Asians, suggesting that chromosome 15q25 may have less 
influence on the risk of lung cancer and smoking behavior in 
Asians than in whites.
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Chromosome 5p15 has also been identified as a putative 
susceptibility locus in lung cancer. This locus contains two 
genes, the telomerase reverse gene, TERT, and the cleft lip and 
palate transmembrane 1-like gene, CLPTM1L.18–20 Several 
SNPs at this locus have been identified, including rs2736100 
and rs402710, and found in replication studies to be associated 
with lung cancer in Asian populations,2 as they were in white 
populations.2–5 These findings are in accordance with those of 
a genome-wide association study in Asian populations.2
Lung cancer has complicated heterogeneity, with the 
major forms (small cell carcinoma [SCC], squamous cell car-
cinoma [SQ], and adenocarcinoma [AD]) showing differences 
in demographic, etiologic, clinical, and molecular character-
istics. A GWAS reported a genetic susceptibility factor that 
affects the specific histology in whites and Asians,21,22 namely 
a locus on chromosome 5p15, which is associated with the 
risk of lung AD. Findings that approximately 25% of patients 
with lung cancer are never smokers, incidence is higher in 
women and those of East Asian ethnicity, and AD is the most 
common histological type6 suggest that risk factors and gene-
environment interactions of lung cancers in ever and never 
smokers may be distinct.
As another susceptibility factor, mutations in epider-
mal growth factor receptor (EGFR) are reportedly common in 
women, never smokers, and Asian patients with lung cancer,23 
and potential differences in the impact of smoking on lung 
cancer risk by EGFR mutational status have been reported.24 
Clarifying the role of the loci at 15q25 and 5p25 in lung can-
cer susceptibility would therefore include an evaluation of 
effect modification by EGFR status.
In this study, to evaluate associations between variants 
at chromosomes 15q25 and 5p15 and the risk of lung can-
cer, and effect modification by smoking and the EGFR status 
of tumors, we conducted a case-control study in 716 patients 
with lung cancer and 716 matched controls in a Japanese 
population.
PATIENTS AND METHODS
Patients
Case subjects were 716 patients with no history of 
cancer who were histologically diagnosed with lung cancer 
between January 2001 and November 2005 at Aichi Cancer 
Center Hospital (ACCH). Control subjects were 716 age- and 
sex-matched first-visit outpatients at ACCH during the same 
period who were confirmed to have no cancer or history of neo-
plasia. Cases and controls were selected from the database of 
the Hospital-based Epidemiologic Research Program at Aichi 
Cancer Center (HERPACC). The framework of HERPACC 
has been described elsewhere.25,26 Briefly, all outpatients aged 
20 to 79 years were asked at first visit to complete a question-
naire regarding their lifestyle and to provide 7 ml of blood 
before any diagnostic procedures were conducted. Responses 
were checked by trained interviewers and used to assess life-
style exposures. Subjects were specifically questioned about 
their lifestyle before the onset of the symptoms, which occa-
sioned their visit to ACCH. Approximately 95% of eligible 
subjects completed the questionnaire and 55% provided blood 
samples. Therefore, 53% of eligible subjects, with the com-
pletion of questionnaires and provision of blood, are chosen 
for case-control studies on genetic risk factors.
Case-control status was determined by data linkage 
between the hospital-based cancer registry and HERPACC 
database. Controls were defined as those who were enrolled 
in HERPACC and confirmed to not have cancer within 1 year 
from the first visit. Case subjects were defined as incident 
cases who had been diagnosed as having lung cancer within 
1 year from the first visit. Approximately 30% of first-visit 
outpatients at ACCH are diagnosed at ACCH as having can-
cer. Under the assumption that the noncancer population 
within HERPACC will visit ACCH if they develop cancer in 
the future, we defined noncancer first-visit outpatients as the 
population from among which such cases may arise. our pre-
vious study confirmed that the lifestyle patterns of first-visit 
outpatients matched the profile of a group randomly selected 
from the general population of Nagoya city, conferring exter-
nal validity on the study.27 Written informed consent was 
obtained from all subjects, and the study was approved by the 
ethics committee of ACC.
Genotyping
The loci examined in this study were rs16969968, 
rs8034191, rs12914385, rs1317286, and rs931794 on 15q25 
and rs2736100 and rs402710 on 5p15, as previously reported 
by Truong et al.2 in the framework of the International Lung 
Cancer Consortium.
DNA was extracted from the buffy coat fraction of each 
subject with a Blood Mini Kit (Qiagen K.K., Tokyo, Japan) 
and assessed using the polymerase chain reaction (PCR) 
Taqman Method28 with a 7500 Fast Real-time PCR system 
(Applied Biosystems, Foster City, CA). Quality of genotyping 
was assessed by duplicate analysis of 5% of samples, which 
showed an agreement rate of 100%. We used a x2 test with 1 
degree of freedom to verify that the allele distribution for each 
SNP was in Hardy-Weinberg equilibrium. No deviation from 
the Hardy-Weinberg equilibrium was observed.
EGFR Mutation Analysis
Assays for EGFR mutations have been described else-
where.24 The majority of tumor samples were analyzed by 
reverse transcription-PCR (RT-PCR) coupled with direct 
sequencing. When frozen tissue for RT-PCR was not avail-
able, the cases were examined with a DNA-based assay using 
formalin-fixed, paraffin-embedded tissue. Both methods have 
been described in detail elsewhere.29–31 Briefly, total RNA 
was isolated using an RNA assay kit (Qiagen, Valenica, CA), 
followed by RT-PCR with a Qiagen oneStep RT-PCR kit 
(Qiagen). The purified PCR products were directly sequenced 
with an ABI PRISM 3100 instrument (Applied Biosystems, 
Foster City, CA). For DNA extracted from paraffin-embed-
ded tissues, we used the cycleave technique with the Smart 
Cycler system (SC-100, Cepheid, Sunnyvale, CA) and frag-
ment analysis with the ABI PRISM 3100 for the detection of 
point mutations of codon 858 and gene deletions in exon 19, 
which together account for approximately 90% of mutations 
in the EGFR gene.32 Accordance of the two methods was 
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99% for codon 858 point mutations and deletions in exon 19, 
and 95% overall.29
Statistical Analysis
odds ratios (oRs) and 95% confidence intervals (CIs) 
were estimated using unconditional logistic regression. 
Information was available for demographic variables (age and 
sex), tobacco exposure, drinking habits, pattern of referral to 
ACCH (physician referral or patient volition), and histological 
classification of cases. Heterozygous and homozygous carri-
ers of the risk allele were compared with heterozygous and 
homozygous carriers of the nonrisk allele, respectively. oRs 
per allele or p values for trends were calculated assuming a 
log-additive genetic model with 1 degree of freedom. In addi-
tion, homozygous carriers of the risk allele were compared 
with carriers of at least one nonrisk allele (recessive model), 
and carriers of at least one risk allele were compared with 
homozygous carriers of the nonrisk allele (dominant model). 
Models were adjusted for potential confounders including 
age, sex, cumulative tobacco consumption, drinking habits, 
and referral pattern where appropriate. Smoking and drink-
ing status at interview were divided into the three categories 
of never, former, and current. Never smokers were defined as 
those who smoked less than 100 cigarettes in their lifetime 
(or before diagnosis for cases) and former smokers as those 
who quit smoking at least 1 year before the time of the survey. 
Cumulative tobacco exposure was expressed as pack-years, 
the product of the number of packs consumed per day and 
years of smoking. Cumulative tobacco exposure was catego-
rized into quartiles according to pack-years among controls, 
namely never (pack-years 5 0), low (pack-years  24), mod-
erate (24  pack-years  40), and heavy (>40 pack-years). 
The association between genetic polymorphisms and lung 
cancer risk was also analyzed by major histological subtype 
(SQ, AD, and SCC). Effect modification was evaluated by a 
test of heterogeneity using stratified analyses by EGFR status, 
histological subtype (AD versus other subtypes), and smok-
ing status (never versus ever) in unconditional logistic model. 
Heterogeneity of oRs across stratification groups was assessed 
under multiplicative assumption, which included an interac-
tion term for genotype and environment variable. We further 
evaluated the joint effect of each polymorphism and cumu-
lative tobacco exposure by comparing groups stratified by 
cumulative tobacco exposure category and the number of risk 
alleles for the risk of lung cancer. In addition to the assessment 
for heterogeneity, joint effect (gene-environment interaction) 
was assessed under multiplicative assumption, which included 
an interaction term for genotype and environment variable. 
For example, products of scores for genotype (0, homozygous 
for nonrisk allele and 1, heterozygous or homozygous for risk 
allele) and smoking status (0, never smoker; 1, ever or 0, never 
smoker; 1, light smoker; 2, moderate smoker; and 3, heavy 
smoker) were included as interaction terms for the heteroge-
neity of oRs across smoking status. p values of 0.05 were 
considered statistically significant. Mean number of cigarettes 
smoked per day was derived from analysis of variance and 
adjusted for age, sex, and case-control status when appro-
priate. All statistical analyses were conducted with STATA 
version 11 (STATA Corp., College Station, TX).
RESULTS
Among case and control subjects, 74.2% were men. The 
prevalence of women (36.5%) was higher among those with 
AD than among the other histological types (3.2% for SQ and 
7.6% for SCC, Table 1). Patients with AD were more likely to 
be never smokers (37.2%) than those with SQ (0%) and SCC 
(3%). EGFR mutational status was available for 333 cases 
(46.7%), among which 120 (16.9%) had the EGFR muta-
tion and 213 (29.8%) did not. Among those with the EGFR 
mutation, 119 (99.2%) were AD. A total of 17% of cases were 
adenocarcinoma with the EGFR mutation.
Table 2 summarizes the main effect of each polymor-
phism. The minor allele frequencies of rs16969968 and 
rs8034191 at chromosome 15q25 were less than 5%, and no 
association with the risk of lung cancer was observed. No asso-
ciation was seen for the other polymorphisms selected from 
this region. In contrast, for chromosome 5p15, we observed 
statistically significant associations between rs2736100 (oR 
5 1.17 [95% CI 5 1.00–1.38], p
trend
 5 0.046) and rs402710 
(oR 5 1.21 [1.03–1.44], p
trend
 5 0.025). Summing the num-
ber of risk alleles for the rs2736100 and rs402710 genotypes 
revealed statistically significant oRs per risk allele (oR 5 
1.14 [1.03–1.25], Table 3).
Table 4 presents the joint effects of smoking status 
(never versus ever) and the selected polymorphisms at chro-
mosomes 15q25 and 5p15 on the risk of lung cancer in the 
dominant model. We observed statistically significant inter-
actions for rs1317286 and rs931794 at chromosome 15q25 
(p 5 0.026 for rs1317286 and p 5 0.001 for 931794). Ever 
smokers without and with the risk allele of rs931794 had a 
higher risk of lung cancer than never smokers without the risk 
allele (oR 5 2.03 [1.34–3.07] for ever smokers without risk 
allele and oR 5 3.24 [2.18–4.84] for ever smokers with risk 
allele). A similar phenomenon was observed with rs1317286. 
For rs2736100 and rs402710 at chromosome 5p15, in con-
trast, no obvious interactive effect was observed. Table 5 
presents the joint effects of cumulative tobacco consump-
tion and polymorphisms at chromosomes 15q25 and 5p15 
on the risk of lung cancer in the dominant model. Compared 
with never smokers without the risk allele of rs931794, oR 
for heavy smokers without the risk allele was 4.03 (95% CI: 
2.45–6.62) and that with it was 8.09 (5.09–12.9), whereas 
the joint effect of rs931734 and cumulative tobacco con-
sumption was statistically significant (p
interaction
  0.001). A 
similar impact was observed with rs12914385 at chromo-
some 15q25. In contrast, however, no such effect was seen 
for polymorphisms on chromosome 5p15 and cumulative 
tobacco consumption.
Stratified analyses of chromosomes 15q25 and 5p15 
showed marginally statistically significant differences in oRs 
estimated by EGFR status for rs16969968 and rs8034191 at 
chromosome 15q25 (p
heterogenity
 5 0.071, respectively, supple-
mental Figs. 1 and 2, http://links.lww.com/JTo/A206). on the 
other hand, no statistically significant differences were seen 
for any SNP at chromosome 5p15. Among SNPs in the 15q25 
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region, stratified analysis revealed a statistically significant dif-
ference in oR estimates by smoking status in the association 
of rs931794 with the risk of lung cancer (p
heterogenity
 5 0.027, 
supplemental Fig. 5, http://links.lww.com/JTo/A206) but not 
for other variants. No association between rs931794 and the 
risk of lung cancer was seen among never smokers (oR 5 0.84 
[0.63–1.16]), whereas among ever smokers, this association 
was statistically significantly stronger in current smokers (oR 
for current smokers 5 1.30 [1.00–1.69]) than never smokers. 
No statistically significant differences in oR estimates were 
seen by histology or age at diagnosis, although a statistically 
significant difference in that by sex was observed in the asso-
ciation between rs931794 and risk of lung cancer (p
heterogenity
 5 
0.003, supplemental Fig. 5, http://links.lww.com/JTo/A206), 
which might reflect the oRs for SQ given that 97% of patients 
with SQ were men. We did not observe any difference in the 
impact of variants in either region by family history of lung 
cancer (data not shown).
We also investigated associations between SNPs at chro-
mosome 15q25 and 5p15 and smoking intensity. overall, the 
mean number of cigarettes smoked per day did not statistically 
significantly differ by genotype for any SNP (data not shown).
DISCUSSION
In this study of lung cancer in a Japanese popula-
tion, we found that the variants rs12914385, rs1317286, and 
TABLE 1. Distribution of Selected Demographic Variables among Case Subjects by Histopathological Type and Controls
Controls
Cases
Total AD SQ SCC
n Percentage n Percentage n Percentage n Percentage n Percentage
Sex
 Male 531 74.2 531 74.2 268 63.5 122 96.8 61 92.4
 Female 185 25.8 185 25.8 154 36.5 4 3.2 5 7.6
Age (yr)
 50 74 10.3 74 10.3 47 11.1 7 5.6 3 4.6
 50–59 197 27.5 196 27.4 134 31.8 22 17.5 16 24.2
 60–69 284 39.7 277 38.7 157 37.2 51 40.5 30 45.5
 70–79 161 22.5 169 23.6 84 19.9 46 36.5 17 74.2
Smoking status
 Never 290 40.5 177 24.7 157 37.2 0 0.0 2 3.0
 Former 233 32.6 168 23.5 93 22.0 39 31.0 13 19.7
 Current 192 26.8 370 51.7 171 40.5 87 69.0 51 77.3
 Ever 425 538 75.2 264 62.5 126 100.0 64 97.0
 Unknown/missing 1 0.1 1 0.1 1 0.2 0 0.0 0 0.0
Pack-years
 Never 290 40.5 177 24.7 157 37.2 0 0.0 2 3.0
 0  pack-years  24 147 20.5 86 12 57 13.5 12 9.5 4 6.1
 24  pack-years  40 133 18.6 111 15.5 57 13.5 26 20.6 12 18.2
 40  pack-years 138 19.3 337 47.1 147 37.8 88 69.8 47 71.2
 Unknown/missing 8 1.1 5 0.7 4 1.0 0 0.0 1 1.5
Drinking status
 Never 248 34.7 274 38.3 178 42.2 42 33.3 17 25.8
 Former 23 3.2 26 3.6 7 1.7 10 7.9 5 7.6
 Current 444 62 415 58 236 55.9 74 58.7 44 66.7
 Unkonwn/missing 1 0.1 1 0.1 1 0.2 0 0.0 0
Family history of lung cancer
 Yes 47 6.6 78 10.9 51 12.1 14 11.1 5 7.6
 No 669 93.4 638 89.1 371 87.9 112 88.9 61 92.4
Referral
 Yes 344 50.6 490 68.4 280 66.4 92 73.0 47 71.2
 No 362 48 219 30.6 139 32.9 33 26.2 17 25.8
 Unknown/missing 10 1.4 7 1 3 0.7 1 0.8 2 3.0
EGFR status
 Mutated 120 16.86 119 28.2 0 0.0 0 0.0
 Wild type 213 29.75 143 33.9 39 31.0 6 31.0
 Unknown 383 53.49 160 37.9 87 69.1 60 69.1
 Total 716 716 422 126 66
n, number of subjects included in analysis; AD, adenocarcinoma; SQ, squamous cell carcinoma; SCC, small cell carcinoma; EGFR, epidermal growth factor receptor.
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rs931794 localized to the CHRNA5-CHRNA3-CHRNB4 
cluster on chromosome 15q25 modified the impact of cig-
arette smoking on lung cancer risk but showed no statisti-
cally significant main effects on the risk of lung cancer. In 
addition, the impact of the 15q25 loci on lung cancer risk 
was found to be independent of nicotine dependence, surro-
gated in this population as the number of cigarettes smoked 
per day. Regarding the TERT-CLPM1L loci on chromosome 
5p15, which is associated with lung cancer risk in whites, this 
association was present in our Japanese population and at a 
similar magnitude. Association with the two variants in 5p15 
was stronger in patients with AD than in those with the other 
histologies combined. We also noted a suggestive difference 
in the impact of rs16969968 and rs8034191 on the 15q25 loci 
by EGFR status on lung cancer risk.
Results showed no significant association between 
the five SNPs at 15q25 and risk of lung cancer or num-
ber of cigarettes smoked per day. These negative findings 
might be partly explained by the low minor allele frequen-
cies of rs16969968 (0.025; Table 2), rs8034191 (0.031), and 
rs1317286 (0.081) and high proportion of never smokers 
(25% of cases and 40% of controls) in the study population. 
The suggestive heterogeneity in the effect of these loci by 
EGFR mutation status might indicate the substantial impor-
tance of these loci even in an Asian population. We found no 
association with the other 15q25 loci, rs1294385 (MAF 5 
0.293) and rs931794 (MAF 5 0.358), which have a higher 
MAF than the other loci examined on 15q25. Interestingly, 
however, we did note that rs1317286 and rs931794 modi-
fied the effect of smoking on the risk of lung cancer. In 
other words, the 15q25 region and smoking have a joint 
effect on the risk of lung cancer. Nicotinic acetylcholine 
receptor subunit genes code for proteins that form receptors 
present in neuronal and other tissues, in particular alveolar 
epithelial cells, pulmonary neuroendocrine cells, and lung 
cancer cell lines,33 and the receptors bind to nicotine and 
nicotine derivatives, including nitrosamines, resulting in 
cell proliferation and neoplastic transformation.34 In addi-
tion, nicotinic acetylcholine receptors also may play a role 
in their repair of wounded bronchial epithelium injured 
by inhaled tobacco carcinogens.35–37 It, therefore, seems 
plausible that genetic variations in nicotinic acetylcholine 
receptors, which affect gene expression or protein func-
tion, modify the impact of smoking on the risk of lung 
cancer by enhancing or impairing cell proliferation, neo-
plastic transformation, and wound repair. Previous studies 
have reported statistically significant associations between 
the D398N amino acid variant in CHRNA5 (rs16969968) 
and the transcript level of this gene in normal tissue,38,39 
between the rs6495309 in CHRNA3 and the ability to bind 
a transcriptional factor,40 and between the 5’ region haplo-
types and promoter ability.41 To our knowledge, our study is 
the first to demonstrate that loci in the 15q25 region modify 
the effect of smoking on the risk of lung cancer. Replication 
in other populations is warranted.
our present findings on cancer susceptibility or smok-
ing traits and chromosome 15q25 loci are inconsistent with 
those of previous studies in Asian populations. For example, 
a Japanese case-control study42 reported associations between T
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the selected SNPs at 15q25 and risk of lung cancer and 
found that associations among never and ever smokers were 
similar. Another large study in China40 identified statistically 
significant associations between four novel SNPs in the 15q25 
region and risk of lung cancer. These associations were sub-
stantially stronger in patients diagnosed at a younger age 
TABLE 3. Association between the Risk of Lung Cancer and Combined Genotypes of rs402710 and 
rs2736100
Combined 
Genotypes
CLPTM1L, 
rs402710
TERT,  
rs2736100
Case Patients 
(n 5 716)
Control Subjects 
(n 5 716) ORa (95% CI) p
No. of risk alleles
 0 AA AA 42 49 1.00 (Reference)
 1 AA AC 15 31 0.56 (0.27–1.19) 0.103
 2 AA CC 3 4 0.88 (0.19–4.13) 0.947
 1 AG AA 118 142 0.97 (0.60–1.57) 0.974
 2 AG AC 152 142 1.25 (0.78–2.00) 0.303
 3 AG CC 37 32 1.35 (0.72–2.53) 0.327
 2 GG AA 88 88 1.17 (0.70–1.94) 0.372
 3 GG AC 173 156 1.29 (0.81–2.06) 0.478
 4 GG CC 88 72 1.43 (0.85–2.39) 0.073
 0 — — 42 49 1.00 (Reference)
 1 — — 133 173 0.90 (0.56–1.44) 0.650
 2 — — 243 234 1.21 (0.77–1.90) 0.403
 3 — — 210 188 1.30 (0.83–2.06) 0.256
 4 — — 88 72 1.43 (0.85–2.39) 0.178
Per risk allele 1.14 (1.03–1.25) 0.008
 0/1 — — 175 222 1.00 (Reference)
 2 — — 243 234 1.40 (1.04–1.86) 0.024
 3/4 — — 298 260 1.46 (1.10–1.93) 0.009
The first section presents data for the association between different combinations of genotypes for rs402710 and rs2736100 and the risk of lung 
cancer. The second and third sections present data for the association between the total number of risk alleles for rs402710 and rs2736100 combined 
and the risk of lung cancer.
p values (two sided) were derived from logistic regression. 
aoRs were adjusted for age, sex, referral pattern, and drinking habit.
—, not applicable; CI, confidence interval; oR, odds ratio.
TABLE 4. Joint Effects of Smoking Behavior and Polymorphisms on chr15q25 and 5p15 in the Dominant 
Model
No. of Risk  
Alleles
Smoking Status
p for  
InteractionbORa (95% CI)—Never ORa (95% CI)—Ever
Chr15q25
 rs16969968 0 1.00 (Reference) 3.30 (2.39–4.54)
1–2 1.26 (0.50–3.18) 4.26 (2.22–8.18) 0.971
 rs8034191 0 1.00 (Reference) 3.20 (2.33–4.41)
1–2 0.82 (0.35–1.94) 3.90 (2.11–7.20) 0.48
 rs12914385 0 1.00 (Reference) 2.64 (1.79–3.91)
1–2 0.90 (0.61–1.33) 3.61 (2.45–5.31) 0.083
 rs1317286 0 1.00 (Reference) 2.92 (2.10–4.06)
1–2 0.78 (0.45–1.36) 4.86 (3.09–7.67) 0.026
 rs931794 0 1.00 (Reference) 2.03 (1.34–3.07)
1–2 0.70 (0.47–1.04) 3.24 (2.18–4.84) 0.001
Chr5p15
 rs2736100 0 1.00 (Reference) 3.26 (2.10–5.05)
1–2 1.17 (0.78–1.76) 3.86 (2.55–5.85) 0.964
 rs402710 0 1.00 (Reference) 3.72 (1.62–8.56)
1–2 1.67 (0.79–3.50) 5.42 (2.57–11.4) 0.757
aoRs are adjusted for age, sex, referral pattern, and drinking habit.
bp for interaction was derived from a log-additive model, which included the interaction term between smoking status (never/ever) and polymorphism.
Ref, reference class; Het, heterozygote; Hom, homozygote for the risk allele; oR, odds ratio; CI, confidence interval.
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and were consistent among never and ever smokers. These two 
studies from Asia might argue for a role of the 15q25 locus 
in lung cancer that is independent of smoking behavior in 
Asians.
Evidence that the 15q25 locus is associated with 
smoking status and nicotine dependence in whites and with 
the risk of lung cancer is unequivocal2,3,8–14,43. Nevertheless, 
investigators disagree about whether the association is 
a direct effect of this region on the risk of lung cancer or 
an indirect effect through nicotine dependence in whites. 
Another study has reported that the contribution of the 
15q25 locus might be greater in African Americans than in 
whites and that the risk might be less likely to reflect an 
indirect effect on lung cancer risk. These findings in dif-
ferent populations suggest a role for racial differences in 
the association between the 15q25 locus, smoking, and risk 
of lung cancer. Consistent with previous studies in Asian 
populations, our findings do not support an indirect effect 
of the 15q25 locus on lung cancer risk by nicotine depen-
dence.2,42 In contrast, modification of the impact of smoking 
by the 15q25 locus might indicate an independent effect of 
this locus on nicotine dependence.
our study identified a statistically significant asso-
ciation between rs2736100 and rs407210 at chromosome 
5p15 and susceptibility to lung cancer in a Japanese popu-
lation. These results are consistent with those of previous 
genome-wide association studies and a replication study in 
whites.2,18–20 In the replication study, Truong et al.2 provided 
conclusive evidence for this association in both Asians and 
whites. Although the physical distance between rs2736100 
and rs402710 on chromosome 5 is approximately 34 kb, 
the LD between two variants is not strong (r2 5 0.06, D´ 
5 0.46), and these associations accordingly appeared to be 
independent. This finding may also suggest the existence 
of an unknown variant which is in LD with rs2736100 and 
rs402710 and which captures the effect of both. Associations 
between these variants and the risk of lung cancer differed 
by histology. We identified an increased risk for ADs with 
both variants and an absence of any risk for SQ and SCC. 
These results are consistent with previous studies in Asian 
populations. Jin et al.44 reported that rs2736100 was associ-
ated with an increased risk of AD in a case-control study in 
a Chinese population, whereas Hsiung et al.21 reported the 
same association with the risk of lung AD in Asian women 
in a GWAS and a replication study conducted in East Asian 
populations.
Evidence suggests that the 5p15 region might be a sus-
ceptibility locus for several cancer types, including head and 
neck, pancreatic, urinary bladder, prostate, skin and cervi-
cal cancer, and glioma.18,45–47 TERT, the reverse transcription 
component of telomerase which is essential for telomerase 
enzymatic activity and the maintenance of telomerase, is 
considered a plausible candidate at 5p15 for lung cancer.48 
Telomerase is responsible for telomere regeneration, and 
high expression or activation of telomerase is observed in 
up to 90% of tumor samples (including lung cancer), sug-
gesting the critical role of TERT in carcinogenesis.48 An 
association between short telomeres and an increased risk 
of several cancers has been reported 18,45–47,49 Variants in the 
TERT region, namely rs401681 and rs273609, were associ-
ated with shorter telomere length in older but not younger 
healthy women, suggesting that these variants may lead to an 
increase in the gradual shortening of telomeres over time.18 
on the other hand, the functions of CLPTM1L are poorly 
understood and a possible role in cancer is a matter of specu-
lation. CLPTM1L has been cloned as a cisplatin-resistance 
TABLE 5. Joint Effects of Cumulative Tobacco Consumption and Polymorphisms on chr15q25 and 5p15 in the 
Dominant Model
No. of Risk  
Alleles Never Light Moderate Heavy
p for  
Interactionb
Chr15q25
 rs16969968 0 1.00 (Reference) 1.48 (0.99–2.21) 2.49 (1.66–3.74) 7.63 (5.24–11.1)
1–2 1.36 (0.53–3.47) 1.37 (0.36–5.32) 2.36 (0.71–7.76) 12.9 (4.81–34.5) 0.806
 rs8034191 0 1.00 (Reference) 1.44 (0.97–2.16) 2.40 (1.60–3.60) 7.45 (5.12–10.8)
1–2 0.85 (0.35–2.01) 1.15 (0.31–4.27) 2.45 (0.81–7.41) 9.99 (4.11–24.3) 0.441
 rs12914385 0 1.00 (Reference) 1.40 (0.86–2.33) 2.26 (1.35–3.77) 5.44 (3.41–8.66)
1–2 0.89 (0.60–1.31) 1.32 (0.79–2.21) 2.31 (1.39–3.85) 9.15 (5.79–14.5) 0.021
 rs1317286 0 1.00 (Reference) 1.29 (0.85–1.96) 2.09 (1.36–3.19) 6.89 (4.68–10.1)
1–2 0.79 (0.45–1.39) 2.22 (1.01–4.87) 3.90 (1.97–7.72) 11.4 (5.99–21.6) 0.091
 rs931794 0 1.00 (Reference) 1.13 (0.65–1.96) 1.77 (1.02–3.07) 4.03 (2.45–6.62)
1–2 0.69 (0.46–1.03) 1.18 (0.71–1.97) 2.19 (1.28–3.51) 8.09 (5.09–12.9) 0.001
Chr5p15
 rs2736100 0 1.00 (Reference) 1.18 (0.65–2.14) 3.15 (1.73–5.73) 7.59 (4.51–12.8)
1–2 1.17 (0.77–1.76) 1.93 (1.15–3.23) 2.48 (1.50–4.13) 9.09 (5.64–14.6) 0.715
 rs402710 0 1.00 (Reference) 1.01 (0.29–3.49) 2.84 (0.90–8.92) 9.28 (3.59–24.0)
1–2 1.65 (0.78–3.49) 2.48 (1.13–5.47) 3.94 (1.78–8.69) 12.5 (5.73–27.2) 0.454
aoRs are adjusted for age, sex, referral pattern, and drinking habit.
bp for interaction was derived from a log-additive model, which included the interaction term between pack-years of smoking and polymorphism.
Ref, reference class; Het, heterozygote; Hom, homozygote for the risk allele; oR, odds ratio; CI, confidence interval.
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factor in ovarian cancer cell lines and associated with apop-
tosis.50 The CLPTM1L lung cancer susceptibility variant 
rs402710 is associated with higher DNA adduct formation 
in the lung.51
our study had several methodological strengths. First, 
it was conducted in a single region in central Japan within the 
framework of the HERPACC study, with a substantial num-
ber of subjects and high response rates (%) to the completion 
of questionnaires and provision of blood. Second, we previ-
ously confirmed that the questionnaire-based lifestyle charac-
teristics in this population are similar to those of the general 
population in Nagoya City in terms of a range of exposures 
of interest to HERPACC-I27 and HERPACC-II (unpublished 
data), supporting the external validity of the study. Third, 
potential confounding factors by age and sex were adjusted 
for by matching. Fourth, given that our allele frequencies were 
comparable with those previously reported in public databases, 
such as HapMap JPT,7 bias in the distribution of selected poly-
morphisms was negligible. Finally, we explored the impact of 
these loci in consideration of EGFR mutation status, which 
is an important genetic characteristic in lung cancer and not 
evaluated with 15q25 and 5p15 loci.
Several potential limitations of the study also warrant 
mention. one methodological issue was the selection of hos-
pital-based outpatients who did not have a diagnosis of cancer 
as controls. Nevertheless, cases and controls were selected 
from the same framework, and most were residents of the 
Tokai area of central Japan, warranting the internal validity of 
this study. In addition, to dilute any bias due to the inclusion of 
a specific diagnostic group related to the exposure of interest, 
we did not set any eligibility criteria for controls other than 
the absence of cancer. Second, the figures for self-reported 
life-style factors considered as potential confounding fac-
tors might have been inaccurate. Any such misclassification 
would be assumed to be nondifferential, however, and likely 
to underestimate the association. Finally, the moderate num-
ber of cases and controls indicates the need for replication of 
our findings in a larger study in a population with the same 
ethnicity.
In conclusion, this study indicates that the 15q25 region 
modifies the well-established effect of smoking on the risk 
of lung cancer in a Japanese population. Further studies to 
replicate the observed interaction are warranted. our findings 
provide clues for understanding lung carcinogenesis and the 
establishment of lung cancer prevention in Asian populations, 
including Japanese population.
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